Adaptimmune Therapeutics (ADAP)

Total liabilities on the balance sheet as of June 2025 : A$0.30 Billion

According to Adaptimmune Therapeutics's latest financial reports the company's total liabilities are A$0.30 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.

Adaptimmune Therapeutics - Total liabilities on balance sheet (from 2014 to 2025)

Total liabilities by year

Year	Total liabilities	Change
2024-12-31	A$0.37 B	5.48%
2023-12-31	A$0.35 B	-1.71%
2022-12-31	A$0.36 B	-0.15%
2021-12-31	A$0.36 B	154.35%
2020-12-31	A$0.14 B	72.84%
2019-12-31	A$82.7 M	95.18%
2018-12-31	A$42.37 M	-57.68%
2017-12-31	A$0.10 B	5.55%
2016-12-31	A$94.85 M
2015-06-30	A$54.13 M	-3.89%
2014-06-30	A$56.32 M	1196.36%
2013-06-30	A$4.34 M	8.8%
2012-06-30	A$3.99 M

Total liabilities for similar companies or competitors

Company	Total liabilities	differencediff.	Country
Novavax NVAX	A$2.00 B	563.01%	🇺🇸 USA
Enzo Biochem ENZB	A$30.25 M	-90.02%	🇺🇸 USA
uniQure QURE	A$0.99 B	227.22%	🇳🇱 Netherlands
Exelixis EXEL	A$0.99 B	228.81%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Adaptimmune Therapeutics (ADAP) - Total liabilities

Total liabilities on the balance sheet as of June 2025 : A$0.30 Billion